The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-04. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Zika outbreak === While Zika has not been reported in India (as of 6 February 2016), on 3 February 2016, Dr Lal PathLabs and other competing pathology labs announced they were preparing Zika test kits. Dr Lal PathLabs reported they plan to sell their kits for Rs 4500 (€60). However, several days later IndiaToday reported: "the Union Ministry of Health pulled up private players, saying they cannot cash in on a public health emergency" and also reported that Dr. Vandana Lal (executive director of Dr Lal PathLabs) stated: "We don't want to talk on this matter. We don't have any tests for Zika virus and we are also not importing any test kits for the same. If at all we plan to do something, we will take the government's prior permission."
C6H4(CO)2NR + N2H4 → C6H4(CO)2N2H2 + RNH2 Alkyl amines can also be used. Some examples of phthalimide-containing drugs include thalidomide, amphotalide, taltrimide, talmetoprim, and apremilast. With a trichloromethylthio substituent, a phthalimide-derived fungicide is Folpet.
=== Regulation of epithelial-mesenchymal transition and metastasis === ITGA1 mediates communication between collagen-rich ECM environments ands transforming growth factor-β (TGFβ) signaling pathways. In pancreatic cancer, ITGA1 promotes TGFβ/collagen-induced epithelial-mesenchymal transition (EMT), which is distinguishable by decreased epithelial markers such as E-cadherin (CDH1) as well as increased mesenchymal markers such as FN1, ZEB1, VIM, and MUC1. Through these mechanisms, ITGA1 promotes cellular plasticity. This is associated with invasion and metastatic progression. ITGA1 is required for efficient metastatic dissemination of living PDAC cells. Loss of ITGA1 reduces tumor spread in experimental models, displaying ITGA1's contribution to metastatic behavior by enabling tumor cells to respond to collagen and TGFβ-rich micro-environments.
===== Type 2M ===== VWD Type 2M results from a loss-of-function mutation in von Willebrand factor (VWF). This mutation leads to reduced binding of VWF with GP1b (similar to VWD Type 2A) or with collagen. Like other Type 2 VWD subtypes, there is a decreased ratio of VWF Activity to antigen. Differentiating VWD Type 2M from Type 2A involves analyzing VWF multimers through electrophoresis. In VWD Type 2M, all multimers are identified but uniformly decreased in quantity, resembling the pattern seen in VWD Type 1. Conversely, in VWD Type 2A, high molecular weight multimers are either absent or present in very low quantities. VWD Type 2M can be further differentiated from VWD Type 1 based on the VWF Activity to antigen ratio. In Type 1, the ratio is >0.7. In Type 2M, the ratio is <0.7. In Type 2M, factor VIII activity can be normal or low while the ristocetin-induced platelet aggregation (RIPA) is typically low. It is uncommon and manifests with moderate to severe bleeding. The disease may follow either an autosomal dominant or recessive pattern of inheritance.
Sources: en.wikipedia.org
The Georgia Train and Equip Program (GTEP) was an American-sponsored 18-month, $64-million program aimed at increasing the capabilities of the Georgian armed forces by training and equipping four 600-man battalions with light weapons, vehicles and communications. The program enabled the US to expedite funding for the Georgian military for Operation Enduring Freedom. On 27 February 2002, the US media reported that the U.S. would send approximately two hundred United States Army Special Forces soldiers to Georgia to train Georgian troops. The program implemented President Bush's decision to respond to the Government of Georgia's request for assistance to enhance its counter-terrorism capabilities and addressed the situation in the Pankisi Gorge. The program was planned to be a 20-month long, $64 million effort. The move drew protests from many Russians. On 1 March 2002, in response to the domestic outcry, Russian president Vladimir Putin met with Georgian president Eduard Shevardnadze in Kazakhstan and pledged his support for the American military initiative. The program began in May 2002 when American special forces soldiers of the 10th Special Forces Group began training select units of the Georgian Armed Forces, including the 12th Commando Light Infantry Battalion, the 16th Mountain-Infantry Battalion, the 13th "Shavnabada" Light Infantry Battalion, the 11th Light Infantry Battalion, a mechanized company, and small numbers of Interior Ministry troops and border guards.
Pickford & de Matos (2026) revise the fossil record of at least three assemblages of Old World monkeys from the Humpata Plateau (Angola), including possible record of a mandrill-like monkey from the middle Pliocene assemblage from Tchiua. A study on the composition of the Old World monkey assemblage (dominated by Colobus sp. and Chlorocebus sp.) from the Pleistocene Markaytoli site (Ethiopia) is published by Smail et al. (2026). Pallas (2026) identifies fossil mandibles from the Pleistocene sites Asbole (Ethiopia) and Koobi Fora (Kenya) belonging to members of the tribe Colobini, including a taxon with similarities to members of the genus Colobus and a taxon with similarities to members of the Piliocolobus-Procolobus lineage. Evidence from the study of tooth wear of Theropithecus oswaldi from the Pliocene strata from Makapansgat and from the Pleistocene strata from Swartkrans (South Africa), indicative of different dietary behaviors of Pliocene and Pleistocene members of the species (with the diet of the Pliocene specimens including more mechanically resistant food), is presented by L'Engle Williams, Schmidt & Remy (2026). Hidalgo-Trujillo et al. (2026) report evidence from the study of tooth wear indicative of dietary differentiation of extinct papionins from the Turkana Basin. Evidence of similarity of molar morphology to those of members of the genus Papio, and likely evidence of opportunistic feeding strategies, is reported in a specimen of Paradolichopithecus aff. arvernensis from the Dafnero-3 site (Greece) by Plastiras et al. (2026); Koutalis et al.
=== Genetic factors === There is a genetic element in individual susceptibility to cellulite. Researchers have traced the genetic component of cellulite to particular polymorphisms in the angiotensin converting enzyme (ACE) and hypoxia-inducible factor 1A (HIF1a) genes. Evidence for the heredity of cellulite is supported by studies showing that both the presence and degree of cellulite is similar between females within the same family.
Sources: en.wikipedia.org
Lean finely textured beef (LFTB)—also called finely textured beef, boneless lean beef trimmings (BLBT), and colloquially known as pink slime—is a meat by-product used as a food additive to ground beef and beef-based processed meats, as a filler, or to reduce the overall fat content of ground beef. As part of the production process, heat and centrifuges remove the fat from the meat in beef trimmings. The resulting paste, without the fat, is exposed to ammonium hydroxide or citric acid to kill bacteria. In 2001, the United States Department of Agriculture (USDA) approved the product for limited human consumption. The product, when prepared using ammonia gas, is banned for human consumption in Canada, and production of all mechanically separated meat from ruminants, including cattle, is prohibited in the European Union. In March 2012, an ABC News series about "pink slime" included claims that approximately 70% of ground beef sold in US supermarkets contained the additive at that time. Some companies and organizations stopped offering ground beef with the product. "Pink slime" was claimed by some originally to have been used as pet food and cooking oil and later approved for public consumption, but this was disputed in April 2012, by both the Food and Drug Administration (FDA) administrator responsible for approving the product, and by Beef Products, Inc. (BPI), the largest US producer of the additive. In September 2012, BPI filed a defamation lawsuit against ABC for false claims about the product. By 2017, BPI was seeking $1.9 billion in damages.
== Contraindications == Diphenhydramine is contraindicated in premature infants and neonates, as well as people who are breastfeeding. It is a pregnancy Category B drug. Diphenhydramine has additive effects with alcohol and other depressants. Monoamine oxidase inhibitors (MAOIs) prolong and intensify the anticholinergic effect of antihistamines.
==== Chorion ==== The chorionic membrane is a fibrous tissue layer containing the fetal blood vessels. Chorionic villi form on the outer surface of the chorion, which maximise surface area for contact with maternal blood. The chorionic villi are involved in fetal-maternal exchange.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.